Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
18.63(c) 18.41(c) 18.07(c) 18.24(c) 18.02(c) Last
462 695 199 395 204 007 321 012 272 631 Volume
-0.43% -1.18% -1.85% +0.94% -1.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -138 M - -
Net cash position 2021 497 M - -
P/E ratio 2021 -8,65x
Yield 2021 -
Sales 2022 1,84 M - -
Net income 2022 -159 M - -
Net cash position 2022 540 M - -
P/E ratio 2022 -7,75x
Yield 2022 -
Capitalization 1 195 M 1 195 M -
EV / Sales 2021 -
EV / Sales 2022 355x
Nbr of Employees 111
Free-Float 94,4%
More Financials
Company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets... 
More about the company
Ratings of Kura Oncology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about KURA ONCOLOGY, INC.
09/13KURA ONCOLOGY : Corporate Presentation - September 2021
PU
09/07KURA ONCOLOGY : to Participate in Two Upcoming Investor Conferences
AQ
08/06KURA ONCOLOGY : Credit Suisse Lowers Kura Oncology's PT to $40 from $42, Updates Model wit..
MT
08/05KURA ONCOLOGY : Q2 Earnings Snapshot
AQ
08/05KURA ONCOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/05KURA ONCOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements ..
AQ
08/05Kura Oncology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/05KURA ONCOLOGY : Reports Second Quarter 2021áFinancial Results
AQ
08/04KURA ONCOLOGY : to Participate in Wedbush PacGrow Healthcare Virtual Conference
AQ
07/29Kura Oncology to Report Second Quarter 2021 Financial Results
GL
07/29KURA ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements and ..
AQ
07/29Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
GL
07/29Kura Oncology, Inc. Appoints Helen Collins, M.D. as Class II Director to its Board of D..
CI
07/06KURA ONCOLOGY : to Collaborate With Novartis on Drug Combination for Head and Neck Squamou..
MT
07/06Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination wi..
GL
More news
News in other languages on KURA ONCOLOGY, INC.

- No features available -

More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 18,02 $
Average target price 44,57 $
Spread / Average Target 147%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-44.83%1 195
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156